Impact of a a pharmaceutical consultation service on palliative care pharmacotherapy

Impact of a a pharmaceutical consultation service on palliative care pharmacotherapy - APMPharmNet

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00007696

Enrollment

Registered

2015-01-20

Start date

2015-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palliative care patients (no specific underlying disease)

Interventions

Group 1: Patients that are admitted to the palliative care unit are followed by pharmacists within a pharmaceutical consultation service. The pharmaceutical intervention pathway of this service consis

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • patients with life-limiting diseases (malignant and non-malignant) • Age > 18 years • admission to the palliative care unit at university hospital Munich or Cologne • Interventiongroup: patients living in or around Munich • patients able to communicate in German or English • informed consent of the patient • life expectancy of at least 4 weeks

Exclusion criteria

Exclusion criteria: patients unable to give consent

Design outcomes

Primary

Measure	Time frame
symptom burden of palliative care patients before and after discharge (measured with integrated Palliative Outcome Scale (IPOS) after admission, before discharge and weekly over 4 weeks after discharge)	—

Secondary

Measure	Time frame
• Drug tolerability (trailmaking-test and anticholinergic load; within 48 h after admission) • Drug-related problems (intervention group only; Pharmaceutical Care Network Europe Drug Related Problems, Priscus-List; during inpatient care) • hospital admission after discharge (within 4 weeks after discharge) • use of the drug information service (intervention group only; within 4 weeks after discharge) • Support by doctor and pharmacist after discharge (within 4 weeks after discharge) • changes to the drug regimen (within 4 weeks after discharge)	—

Measure

Time frame

• Drug tolerability (trailmaking-test and anticholinergic load; within 48 h after admission) • Drug-related problems (intervention group only; Pharmaceutical Care Network Europe Drug Related Problems, Priscus-List; during inpatient care) • hospital admission after discharge (within 4 weeks after discharge) • use of the drug information service (intervention group only; within 4 weeks after discharge) • Support by doctor and pharmacist after discharge (within 4 weeks after discharge) • changes to the drug regimen (within 4 weeks after discharge)

—

Countries

Germany

Contacts

Public ContactConstanze Rémi

Klinikum der Universität MünchenKlinik und Poliklinik für Palliativmedizin

constanze.remi@med.uni-muenchen.de+49(0)89 4400-74922

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026